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Abstract
Bcl-2, a prosurvival protein, regulates programmed cell death during development and repair
processes, and can be oncogenic when cell proliferation is deregulated. The present study
investigated what factors modulate Bcl-2 expression in airway epithelial cells and identified the
pathways involved. Microarray analysis of mRNA from airway epithelial cells captured by laser
microdissection showed that increased expression of IL-1β and IGF-1 coincided with induced
Bcl-2 expression compared to controls. Treatment of cultured airway epithelial cells with IL-1β
and IGF-1 induced Bcl-2 expression by increasing Bcl-2 mRNA stability with no discernible
changes in promoter activity. Silencing the IGF-1 expression using shRNA showed that
intracellular (IC)-IGF-1 was increasing Bcl-2 expression. Blocking EGFR or IGF-1R activation
also suppressed IC-IGF-1, and abolished the Bcl-2 induction. Induced expression and co-
localization of IC-IGF-1 and Bcl-2 were observed in airway epithelial cells of mice exposed to
LPS or cigarette smoke and of patients with cystic fibrosis and chronic bronchitis but not in the
respective controls. These studies demonstrate that IC-IGF-1 induces Bcl-2 expression in
epithelial cells via IGF-1R and EGFR pathways, and targeting IC-IGF-1 could be beneficial to
treat chronic airway diseases.
Introduction
Bcl-2, a prosurvival protein, was first identified in the most common translocation in human
B cell follicular lymphoma (1, 2) and was found to have oncogenic properties by inhibiting
cell death rather than by promoting cell proliferation. Bcl-2 frequently overexpressed in
cancer cells is associated with resistance of cytotoxic anticancer drugs and poor clinical
outcome (3), and downregulation of Bcl-2 restores the intrinsic apoptotic pathways with
antitumor effects (4). Bcl-2 plays a key role in normal cellular homeostasis by regulating the
integrity of the mitochondrial and endoplasmic reticulum membranes and is involved in an
array of apoptotic and autophagic programs during development and repair processes (5, 6).
Particularly, Bcl-2 is essential for developmentally programmed cell death of renal epithelial
progenitors, and of mature B and T lymphocytes (5) and for epithelial injury and repair
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processes (7) that can lead to chronic inflammatory diseases. Pulmonary inflammation
induced by viral or bacterial infections or by chronic exposure to environmental pollutants
initiates airway epithelial cell proliferation and induced expression of Bcl-2 to sustain
proliferating epithelial cells (8, 9). Gain- and loss-of-function studies showed that Bcl-2
expression sustains hyperplastic epithelial cells, and Bcl-2 expression is elevated in airway
mucous cells of subjects with cystic fibrosis (7) and in airway epithelium of asthmatics (10).
Therefore, identification of inflammatory mediators that regulate Bcl-2 expression in airway
epithelial cells may provide useful targets for developing novel intervention strategies.
Several cytokines including TNF receptor-associated factors link transmembrane receptors
to the NF-κB pathway to increase Bcl-2 expression (11–13). Both, IL-6 and IL-7 up-
regulate Bcl-2 to increase survival in T lymphocytes by activating STAT3 (14) or viability
and proliferation of T cell acute lymphoblastic leukemia cells, respectively (15). IL-3, IL-4,
and IGF-I increase Bcl-2 expression to protect promyeloid cells from apoptosis (16). In
contrast, IL-2 limits continued T-cell expansion by reducing Bcl-2 expression and rendering
cells susceptible to apoptotic cell death (17) and TGF-β controls effector CD8+ T cell
numbers by lowering Bcl-2 expression and selectively promoting apoptosis of short-lived
effector cells (18). While these studies establish the role of cytokines and growth factors in
hematopoietic cells, the inflammatory mediator(s) that regulate Bcl-2 expression in airway
epithelial cells are unknown.
Recently, EGFR-dependent pathway was associated with epithelial cell survival and shown
to be critical for remodeling of airway epithelium toward chronic mucous hypersecretory
phenotype, but the mechanism of epithelial cell survival was not identified (19). Thus, this
study also investigated whether Bcl-2 expression is involved in the EGFR-mediated airway
epithelial cell survival mechanisms.
Materials and Methods
Human subjects and lung tissue analysis
Lung tissue specimens from subjects with cystic fibrosis were obtained under protocols
approved by the University of North Carolina at Chapel Hill Office of Human Research
Ethics Institutional Review Board. The lung specimens with the CFTR mutation were
rapidly procured from individuals undergoing lung transplantation for end stage lung disease
and specimens from non-CF controls were excess portions of donor lungs that were trimmed
for size matching. Demographics of these subjects are shown in Table 1. Specimens were
fixed by immersion in neutral buffered formalin and conventionally processed for paraffin
embedding and sectioning. The lung tissue specimens from subjects diagnosed with chronic
bronchitis and non-diseased controls (Table 2) were obtained from Lung Tissue Research
Consortium (LTRC) that is sponsored by the National Heart Lung and Blood Institute.
Laboratory animals
Specific pathogen-free F344/NCrR male rats of 6–8 wk of age were obtained from NCI
(Frederick, MD) and were housed until 8–10 weeks of age. The rats were housed in pairs
and were provided food and water ad libitum, a 12-h light/dark cycle at 22.2°C, and 30–40%
humidity. Rats were weighed and randomly assigned to each experimental group. Pathogen-
free wild-type C57BL/6J mice were purchased from The Jackson Laboratory. Mice were
housed in isolated cages under specific pathogen-free conditions. All experiments were
approved by the Institutional Animal Care and Use Committee and were conducted at
Lovelace Respiratory Research Institute, a facility approved by the Association for the
Assessment and Accreditation for Laboratory Animal Care International.
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For intratracheal instillations, rats were briefly anesthetized with 5% isoflurane in oxygen
and instilled intratracheally with 1000 µg of LPS (Pseudomonas aeruginosa serotype 10, lot
31K4122, 3,000,000 LPS units (EU)/mg, Sigma, St. Louis, MO) in 0.5 ml of 0.9% pyrogen-
free saline. Control rats were instilled with 0.5 ml of 0.9% pyrogen-free saline.
LCM and microarray analyses
The right lungs of F344/NCrR male rats at 0 and 2 d post LPS instillation were snap-frozen,
and stored at −80°C after inflating with diluted (1:4 in PBS) Tissue-Tek O.C.T. (EMS
Biosciences, Hatfeild, PA). Frozen tissue sections (8 µm thick) were fixed, dehydrated, air-
dried, and epithelial cells from five large airways of each rat were captured using the laser
onto Arcturus® CapSure® HS LCM Caps (Applied Biosystems, Foster City, CA). Total
RNA was extracted from the cellular lysate in the cap using the PicoPure® RNA Isolation
Kit (Applied Biosystems) and mRNA were amplified using the RiboAmp RNA
amplification kit (Applied Biosystems) as recommended by the manufacturer’s instructions.
Epithelia microdissected from eight tissue sections resulted in an average 1000 ng of
amplified RNA. A second round of amplification was carried out and the biotinylated cRNA
probes were then prepared. Microarray analysis was performed using a rat microarray chip
RG-U34A (Affymetrix Inc., Sunnyvale, CA). All datasets have been deposited at National
Center for Biotechnology Information/Gene Expression Omnibus under accession number
GSE36174 (http://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE36174).
Cell culture treatments and quantitative RT-PCR
Immortalized rat airway epithelial cells, SPOC-1 cells were maintained as described (20,
21). The human airway epithelial cells, AALEB cells (22) and primary human airway
epithelial cells (HAECs, Clontech, Walkersville, MD) were maintained in bronchial
epithelial growth medium (BEGM, Lonza, Walkersville, MD). The SPOC-1 cells were
treated with rat IL-1β (5 ng/ml), IL-6 (1 ng/ml), IL-9 (0.01 ng/ml), VEGF (5 ng/ml), TNFα
(1 ng/ml), IGF-1 (100 ng/ml) or left untreated. The AALEBs and HAECs were treated with
human IGF-1 and human IL-1β (R&D systems, Minneapolis, MN). Cells were also pre-
treated with Picropodophyllin or PPP (Santa Cruz Biotechnology, Santa Cruz, CA), an
inhibitor of IGF-1R activation or various inhibitors of EGFR tyrosine kinase activation,
AG1478 (Santa Cruz Biotechnology, Santa Cruz, CA), EKB-569 or PD153035 (Selleck
Chemicals, Houston, TX) for 2 h with no effect on cell viability prior to the treatment with
IGF-1 or IL-1β. RNA was isolated from the snap-frozen right lungs of animals using TRIzol
as described previously (22) whereas RNA from cultured cells was extracted using the
RNeasy kit (Qiagen, Valencia, CA). The primer/probe sets for IL-1b, IGF-1, Bcl-2,
MUC5AC and CDKN1B were obtained from Applied Biosystems (Foster City, CA) and
were amplified by quantitative real-time PCR using RT-PCR Master Mix (Applied
Biosystems, Foster City, CA) in the ABIPRISM 7900HT Real-Time PCR System. Relative
quantities were calculated by normalizing averaged CT values to CDKN1B or 18S to obtain
ΔCt, and the relative standard curve method was used for determining the fold change as
described previously (23).
Western blot analysis
Protein was extracted from the right lungs of LPS instilled rats by homogenization in RIPA
buffer (10 mM Tris, pH 7.4, 150 mM NaCl, 1% Triton X-100, 1% deoxycholate, 0.1% SDS,
and 5 mM EDTA) supplemented with a protease inhibitor cocktail (Sigma Chemical Co., St.
Louis, MO) at 1:100 final concentration. Protein concentration was determined using the
BCA kit (Pierce, Thermo Fisher Scientific, Rockford, IL) and 100–150 µg of protein lysate
was analyzed by Western blotting. The Bcl-2, IGF-1, EGFR and β-actin were detected using
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appropriate peroxidase-conjugated secondary antibodies and visualized by
chemiluminescence (Perkin Elmer, Waltham, MA) using the FujiFilm Image Reader
LAS-4000 (Valhalla, NY).
Immunofluorescent staining and image analysis
Lung sections were deparaffinized, hydrated in graded ethanol and deionized water, then
washed in 0.05% v/v Brij-35 in Dulbecco's PBS (pH 7.4). The antigens were unmasked by
treating with Digest-All kit (Zymed Laboratories, San Francisco, CA) at a 1:3 dilution of
trypsin to diluent at 37°C for 10 min. Sections were then blocked using 0.2% Triton X-100
with 0.2% Saponin in a blocking solution containing 3% IgG-free BSA, 1% Gelatin and 2%
normal donkey serum followed by incubation with anti-Bcl-2 (N19, Santa Cruz Biotech,
CA), anti-IGF-1 (H70, Santa Cruz Biotech, CA), or isotype controls at 1:200 dilution. The
immunolabeled cells were detected using F(ab)2-fragments of respective secondary
antibodies conjugated to either DylightTM-549 or DylightTM-649 (Jackson Immunoresearch,
West Grove, PA) at 1:1000 dilution and mounted with 4',6-diamidino-2-phenylindole
(DAPI) containing Fluormount-GTM (SouthernBiotech, Birmingham, AL) for nuclear
staining. For cytometry, cells were grown on Lab-Tek-II 8-chamber slides (Nalge Nunc
International, Rochester, NY) and treated with 100 ng/ml of IGF-1 or 5ng/ml of IL-1β or
were left untreated and were fixed using 3% paraformaldehyde with 3% sucrose in PBS and
processed for immunostaining as described above. Quantification of Bcl-2-positive and
IGF-1-positve cells per mm of basal lamina was performed using the VisioMorph system
(Visiopham A/S, Horsholm, Denmark).
mRNA half-life analysis
Cells were treated with the RNA polymerase inhibitor 5,6-dichloro-1-beta-D-
ribobenzimidazole (DRB) (Sigma-Aldrich, St. Louis, MO) at a final concentration of 100ng/
ml to block RNA polymerase activity and harvested at 0, 0.5, 1, 2, 4, 6, 8, 12, and 24 h post-
treatment. The relative mRNA abundance was calculated using the ∆∆Ct method, and
mRNA half-life was calculated using the Greenberg formula (24).
Bcl-2 promoter constructs and transfection
The generation of the P1–P2, P1, and P2 luciferase constructs has been previously described
(25). The P1 promoter region is the main driving force for transcribing the Bcl-2 gene and
P1 activity is suppressed by the P2 region (25). The P2 region (681 bp) was cloned in
pCR2.1 vector to obtain P2-TA construct and various deletion mutants were generated by
using standard techniques. The full-length mutant P2 construct (mut-P2) was generated by
purine-pyrimidine substitutions (Mutagenex Inc., NJ) to fully destroy the consensus Brn3a-
interacting region at residues 93–99. All transient transfections were carried out in 24 well-
plates (USA Scientific, Orlando, FL) using Fugene 6.0 reagent (Roche Applied Biosystems,
Indianapolis, IN) as described previously (25).
LPS instillation
Male C57BL/6 mice at 8–10 wks of age were briefly anesthetized with 5% isoflurane in
oxygen and instilled intranasally with 60 µg of LPS (Pseudomonas aeruginosa serotype 10,
lot 31K4122, 3,000,000 LPS units (EU)/mg, Sigma, St. Louis, MO) in 0.05 ml of 0.9%
pyrogen-free saline. Control mice were instilled with 0.05 ml of 0.9% pyrogen-free saline.
Mice were sacrificed 3 d post-instillation and lung tissues were processed and analyzed.
Exposure to cigarette smoke
Male C57BL/6 mice at 8–10 wks of age were exposed whole-body to mainstream CS or
filtered air (FA) as described previously (26). Mice were acclimated to the CS exposure at
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100 mg/m3 of total particulate material (TPM) for the first week and then exposed to CS
concentration at 250 mg/m3 TPM for the following 22 wk. CS was generated from 2R4F
filtered research cigarettes (University of Kentucky Tobacco Research and Development
Center, Lexington, KY) using the AMESA Type 1300 smoking machine. Mice were
sacrificed post-exposure and lung tissues were processed and analyzed.
IGF-1 gene silencing by shRNA transfection
AALEB cells were transfected with IGF-1 shRNA containing retroviral vectors or control
vectors (Origene Technologies, Inc., Rockville, MD) as per manufacturer’s instructions.
After infection with IGF-1 or control shRNAs, cells were treated with 20 ng/ml human
IL-1β, and 48 h later cells were assessed for IGF-1 expression.
Statistical analysis
Grouped results were expressed as means ± SEM. Data were analyzed using GraphPad
Prism Software (GraphPad Software, Inc., San Diego, CA). Grouped results were analyzed
using two-way analysis of variance. When significant main effects were detected (P < 0.05),
Fishers least significant difference test was used to determine differences between groups.
Results
Microarray analysis of laser-capture microdissected airway epithelia
Previously, we observed increased number of Bcl-2-positive epithelial cells in rats exposed
to LPS, specifically on day 2 post LPS challenge (7). Thus, to identify the mediators
involved in upregulation of Bcl-2 expression, we microdissected airway epithelial cells by
laser-capture microscopy (Fig. 1A) from lungs of non-instilled rats or 2 d post LPS-
exposure. Microarray profiling of the mRNA isolated from the dissected epithelial cells on
rat RGU34A chips revealed 800 differentially expressed genes (p<0.05), and the heat map of
the differentially expressed genes displayed consistent gene expression patterns among
individual rats in the same treatment group (Fig. 1B). Among the 800 genes, there were 137
growth factors, 51 cytokines and 44 apoptosis-related genes (Fig. 1C). The most
significantly induced genes (2–6-fold) were IGF-1, IL-1α, IL-1β, eotaxin, MCP-1, MIP-2,
and MIP-3α; however, IGFBP3 levels were downregulated by 3-fold in LPS-treated rats.
Highly induced expression of IGF-1 and IL-1β along with that of elevated MUC5AC levels
was validated by qRT-PCR (Fig. 1D). Consistent with previous observations, Bcl-2 mRNA
was also found to be 1.9-fold higher in LPS-exposed rats compared to non-instilled controls
(Fig. 1D).
IL-1β and IGF-1 induce Bcl-2 expression in airway epithelial cells
We first tested the effect of the candidate inflammatory factors, IL-1β and IGF-1, on Bcl-2
expression by treating AALEB cells, a human airway epithelial cell line, with recombinant
human IL-1β and IGF-1. A significant induction of Bcl-2 mRNA levels was consistently
observed following IGF-1 (Fig. 2A) and IL-1β (Fig. 2B) treatments. Similar results were
observed in SPOC-1 cells, a rat airway epithelial cell line, following treatment with
recombinant rat IL-1β and IGF-1 (Fig. S1). Accordingly, 100 ng/ml of IGF-1 and 5 ng/ml of
IL-1β were chosen for further analysis and resulted in increased Bcl-2 protein levels as
analyzed by Western blot (Fig. 2C) and immunofluorescent staining (Fig. 2D) analyses.
Intracellular IGF-1 mediates Bcl-2 upregulation via EGFR and IGF-1R pathways
EGFR pathway has been shown to be essential in cell survival and proliferation pathways,
therefore we tested whether IL-1β- and IGF-1-medaited induction of Bcl-2 requires EGFR
pathway. For this purpose, AALEB cells were treated with IGF-1 or IL-1β in the presence
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and absence of a specific EGFR kinase inhibitor, AG1478. The pretreatment of cells with
AG1478 abolished the IGF-1- and IL-1β-mediated increase in Bcl-2 mRNA levels (Fig.
3A). Pretreatment with other EGFR kinase inhibitors, PD153035 and EKB-569, a potent
irreversible inhibitor, also showed identical results (Fig. S2). Because IL-1β was previously
shown to induce IGF-1 (27), we hypothesized that IL-1β mediates IGF-1 and Bcl-2
expression. To test this hypothesis, AALEB cells were pretreated with specific IGF-1R
tyrosine kinase inhibitor, PPP followed by IGF-1 or IL-1β treatment. Both IGF-1 and IL-1β-
medaited increase in Bcl-2 mRNA levels was abolished with PPP pretreatment (Fig. 3A).
Furthermore, both IGF-1 and IL-1β treatment increased the immunopositivity for
intracellular (IC)-IGF-1 and Bcl-2 by 4–5-fold and IC-IGF-1 and Bcl-2 were co-localized in
the same cells (Fig. 3B). Bcl-2 was absent in cells lacking IC-IGF-1 expression and
pretreatment with either AG1478 or PPP suppressed this effect (Fig. 3B). Similar results
were obtained when IGF-1R and EGFR were inhibited in SPOC-1 cells treated with rat
IGF-1 and rat IL-1β (Fig. S3).
In order to understand the kinetics of Bcl-2 induction, we determined the expression of
Bcl-2 in HAECs by immunofluorescence staining of cells treated with IGF-1 or IL-1β for 1,
2, 3, 4, 8 and 12 h. Compared to untreated cells, both IGF-1 and IL-1β treatments showed
increase in Bcl-2-posiitve cells already at 1 h post-treatment with further increases in Bcl-2-
positive cells at later time-points (Fig. 3C). However, there were no significant differences
between the two treatments. The role of IC-IGF-1 in inducing Bcl2 expression was
investigated by blocking its expression using shRNA specific for IGF-1 (shIGF-1). The
IL-1β-induced expression of both IC-IGF-1 and Bcl-2 were completely suppressed
compared to control shRNA transfected cells (Fig. 3D).
Because IC-IGF-1 appeared to be central in increasing Bcl-2 expression, we examined
whether IGF-1 induces Bcl-2 expression in airway epithelial cells in vivo, by instilling rats
with IGF-1 intratracheally and harvesting lungs at 24h for immunostaining. Bcl-2-positivity
of airway epithelial cells was increased by 2-fold compared to vehicle-instilled group (Fig.
3E). Thus, IGF-1 induced Bcl-2 expression in airway epithelial cells both in-vitro and in-
vivo.
Collectively, these data suggest that Bcl-2 expression is upregulated by IC-IGF-1 via
convergence of EGFR and IGF-1R pathways.
IGF-1 increases Bcl-2 mRNA stability
We tested whether IGF-1 induces Bcl-2 promoter activity by transfecting AALEB cells with
various Bcl-2 promoter luciferase reporter constructs described earlier (25). However, no
changes in luciferase activity were observed following IGF-1 treatment (Fig. S4 A),
suggesting that transcriptional activity was not affected. However, IGF-1 increased Bcl-2
mRNA half-life by ~4.6-fold in AALEB cells (Fig. 4A). Because the Bcl-2 mRNA contains
the P2 region upstream of the transcriptional start site (25), we investigated whether merely
transfection with plasmids containing this upstream region may compete for mRNA
degrading factors and thereby affect Bcl-2 mRNA levels in IGF-1-treated cells.
Interestingly, cells transfected with the constructs containing only the P2 promoter region
consistently showed enhanced increase in Bcl-2 mRNA levels compared to those transfected
with empty vector when treated with IGF-1 (Fig. 4B). Similar results were obtained when
cells transfected with P2 promoter constructs were treated with IL-1β (Fig. S4 B). These
highly reproducible findings suggested that P2 region may interact with mRNA destabilizing
factors that facilitate the IGF-1-mediated stability of Bcl-2 mRNA.
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In order to identify the minimum possible sub-region within P2 that was responsible for
facilitating IGF-1-induced Bcl-2 mRNA stability, we generated various P2 deletion-
constructs and a mutant P2 (mut-P2) construct with substitutions at 93–99 region that would
destroy the Brn3a-interacting site (28) (Fig. 4C). Following IGF-1 treatment, the cells
transfected with D1 (1–356) and D2 (1–126) deletion constructs showed IGF-1-induced
increase in Bcl-2 mRNA while cells transfected with D3 deletion construct (1–106) and
mut-P2 construct failed to show any change (Fig. 4C). These findings suggest that the region
91–108 previously shown to interact with Brn3a (29) is involved with IGF-1-induced
stabilization of Bcl-2 mRNA.
IC-IGF-1 and Bcl-2 are co-expressed in epithelial cells of chronic inflammatory airways
We next tested whether IC-IGF-1 and Bcl-2 are expressed in animal models, and more
importantly, in subjects with chronic airway diseases. As reported earlier (7–9), Bcl-2
mRNA levels were increased significantly in LPS- compared to saline-instilled rats (Fig.
5A). The airway epithelial cells when analyzed for IC-IGF-1 and Bcl-2 immunopositivity
showed a 9- and 11-fold increase, respectively, in LPS-instilled mice compared to saline-
instilled controls (Fig. 5B). In addition, in cystic fibrosis (CF) the percentage of Bcl-2
positive epithelial cells is significantly increased compared to non-diseased controls (7).
Because the present study shows that IC-IGF-1 is crucial for inducing Bcl-2 expression, we
immunostained airway tissues from CF and controls with antibodies to IC-IGF-1 and Bcl-2.
We found that in subjects with CF the number of IC-IGF-1- and Bcl-2-positive AECs/mm
BL was increased 3- and 7-fold compared to normal subjects, respectively (Fig. 5C).
In a mouse model of chronic cigarette smoke (CS) exposure we observed a 4-fold increase
in Bcl-2 mRNA levels in CS-exposed mice compared to filtered-air (FA) controls (Fig. 5D).
When airway tissues were analyzed by immunofluorescence we observed a 7- and 4-fold
increase in the IC-IGF-1- and Bcl-2-positive cells in CS-exposed mice compared to FA-
exposed mice, respectively (Fig. 5E). Similarly, in lung tissues from former smokers with or
without chronic bronchitis, IC-IGF-1- and Bcl-2-positive cells were 7- and 5-fold increased,
compared to subjects with no chronic bronchitis, respectively. As was observed for cells in
culture, IC-IGF-1 and Bcl-2 were colocalized in airway epithelial cells (Fig. 5F).
Discussion
The present study identifies IL-1β and IGF-1 as the principal inflammatory mediators that
induce Bcl-2 expression in airway epithelial cells. Induction in Bcl-2 expression involved
both EGFR and IGF-1R pathways, and required the expression of ‘intracellular’ IGF-1.
Several observations suggest that not the ‘secreted IGF-1’ but the intracellular(IC)-IGF-1
mediates induction in Bcl-2 expression. First, IGF-1 treatment of airway epithelial cells
increased IC-IGF-1 and Bcl-2 levels both in-vitro and by intratracheal instillation of rats in-
vivo. Second, immunofluorescent analysis of IL-1β-treated cells showed that IC-IGF-1 and
Bcl-2 are co-localized in the same cells, while cells without IGF-1-positivity were Bcl-2-
negative. Third, IL-1β-treatment of airway epithelial cells resulted in robust IC-IGF-1
expression and blocking IC-IGF-1 expression using shRNA suppressed Bcl-2 expression.
Collectively, these data show that IL-1β and IGF-1 lead to induced Bcl-2 expression via
upregulating IC-IGF-1. The mechanism by which IL-1β induces IC-IGF-1 is not clear.
However, similar results were observed in prostate epithelial cells and in cardiac cells,
where IL-1β induces anti-apoptotic and proliferative phenotype by upregulating IGF-1
transcription using the Janus activated kinase-signal transducer and activator of transcription
(JAK-STAT) pathway (27, 30). The molecular mechanisms by which IL-1β induces IC-
IGF-1 in airway epithelial cells are yet to be defined
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In airway epithelial cells, EGFR pathway has been identified as a common denominator for
proinflammatory responses that aide in epithelial cell hyperplasia and mucous cell
metaplasia (19, 31–33). Tyner et al. (19) proposed that the EGFR pathway is associated with
survival of airway epithelial cells in response to a viral challenge. However, the mechanism
of EGFR-induced survival airway epithelial cells was not identified. Our data show that
EGFR activation by inflammatory mediators result in induced Bcl-2 expression and present
a new paradigm that EGFR activation sustains airway epithelial cells by inducing the
antiapoptotic protein, Bcl-2. These findings are consistent with other studies which report
TGFα-induced activation of EGFR mediates Bcl-2 induction in NCI-H292 cells (34) and in
gastric mucosal cells (35). Moreover, the external stimuli such as exposure to ozone, LPS,
CS, or allergen sensitization that upregulate Bcl-2 expression (36) are also known to activate
EGFR in airway epithelial cells (37, 38). EGFR and IGF-1R pathways and their ligands
have been shown to cross-talk, but mostly in transformed cells, with IGF-1 induction
resulting in secretion of the EGFR ligands, TGFα and amphiregulin, and blocking of EGFR
activation abolished the IGF-1R stimulated intracellular pathways (39, 40). In addition,
continuous EGF stimulation required a functional IGF-1R pathway that resulted in ERK
activation in mouse fibroblasts (41, 42). The observed increase in Bcl-2 immunopositivity as
early as an hour post treatment indicates rapid convergence of these pathways leading to
Bcl-2 induction.
Besides epithelial cell proliferation and survival signaling, EGFR mediates MUC5AC
synthesis following exposure to LPS-, CS-, or infection with Pseudomonas aeruginosa (31,
37, 38). Interestingly, EGFR activation causes MUC5AC and Bcl-2 expression, (33, 34) and
Bcl-2 expression sustains epithelial cell hyperplasia (7). Future studies will investigate
whether Bcl-2 expression directly mediates MUC5AC expression. Moreover, Bcl-2 binds
and suppresses NALP1, an integral component of inflammasome, to reduce caspase-1,
originally identified as IL-1β-converting enzyme activation and, thus, inhibits IL-1β
production (43, 44). Together, the present data suggest that the inflammatory mediators such
as IL-1β and IGF-1 stimulate EGFR and IGF-1R pathways that converge to induce IC-
IGF-1 to help upregulate Bcl-2 expression in epithelial cells, and induced Bcl-2 expression
could, in a negative feedback mechanism, suppress inflammation (Fig. 6).
Bcl-2 expression is regulated at the transcriptional and post-translational levels. The P1
region harbors the positive regulatory elements for Bcl-2 transcription (25, 45) and the P2-
region suppresses the P1 activity (25). Transcriptional factors such as the CREB and SP-1
(46, 47) interact with the P1 region to upregulate its transcriptional activity while factors
such as nuclear NF-κB (11), Brn3a (29), C/EBP (46), and p53 (25) interact with the P2
region to either suppress or enhance its inhibitory role. However, in our experimental setting
IGF-1 did not affect the promoter activity of various luciferase-reporter constructs
containing Bcl-2 promoter regions. Instead, IGF-1 treatment stabilized Bcl-2 mRNA
resulting in increased Bcl-2 mRNA levels. While the repressor that binds to the P2 region
plays an important role in regulating Bcl-2 transcription as shown in our previous study (25),
the lack of IGF-1 affecting the Bcl-2 promoter region suggests that IGF-1-induced Bcl-2
mRNA stability is not mediated by this repressor. However, cells that were transfected with
a plasmid containing the P2 region consistently showed an additional increase in Bcl-2
mRNA when treated with IGF-1. In the absence of IGF-1, the transfection of P2 construct
alone had no affect on Bcl-2 mRNA suggesting that the P2 region, when transfected as part
of a plasmid, did not affect the repressor function of the P2 region. Taken together, these
data suggest that the repressor-binding potential of the P2 region is not playing a role in the
context of IGF-1-mediated induction of Bcl-2 mRNA. Therefore, we conclude that IGF-1
increased Bcl-2 mRNA stability by P2 serving as a sink for the putative destabilizing
factor(s). Previous studies have shown that the P2 repressor activity is mediated by the
region 412–607 that includes a 195 bp p53-dependent negative regulatory element. The
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present study showed that deleting the region 106–126 or mutating the core Brn3a binding
site (28), 93–99, is sufficient to disrupt the IGF-1-mediated enhancement of Bcl-2 mRNA
when transfecting the P2 region. These findings suggest that the regions interacting with the
putative destabilizing factor and repressor are non-overlapping. Whether the repressor
binding to the P2 region is competed out by the destabilizing factor causing steric
hindrances or whether other factors are involved to exclude repressor binding to the
transfected P2 region will require additional studies. Nonetheless, both IL-1β and IGF-1
induced the Bcl-2 mRNA in cells transfected with P2 promoter region implicating a
common mechanism that likely involves IC-IGF-1. Stabilization of Bcl-2 mRNA has been
recently reported as one of the mechanism by which Bcl-2 is upregulated in cancer cells (48,
49). Further studies will be carried out in identifying the mechanism(s) that mediates IGF-1
induced Bcl-2 mRNA stabilization but are beyond the scope of the present study.
In mouse models of acute or chronic lung injury using LPS or CS, respectively, we observed
increased number of IC-IGF-1- and Bcl-2-positive airway epithelial cells. Similar findings
in autopsied lung airways from patients with cystic fibrosis and chronic bronchitis suggest
that this pathway is of clinical relevance and should be exploited to help regulate chronic
airway epithelial inflammation. However, the numbers of IC-IGF-1-positive cells were
consistently higher than the Bcl-2-positive cells, suggesting that IC-IGF-1 expression is
upstream of Bcl-2 induction, and also that IC-IGF-1 may be involved in other prosurvival
mechanisms besides Bcl-2 induction. It is also possible that as yet unknown factors or
pathways affect IC-IGF-1-induced Bcl-2 expression in airway epithelial cells. Of an
important note, Bcl-2 as a proto-oncogene is implicated in several cancers, including
melanoma, breast, prostate, and lung carcinomas (3, 11, 50, 51), and IGF-1 and IGF-1R
levels have been positively correlated with tumor progression (52, 53). In addition, EGFR,
when constitutively active due to mutations, promotes carcinogenesis (54) and when
heterodimerized with IGF-1R monomers (55) may enhance Bcl-2 expression. Therefore, the
IC-IGF-1-mediated Bcl-2 induction could be one of the early molecular changes that sustain
inflammation-induced hyperplasia and could be the germinal centers for preneoplastic
lesions.
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Refer to Web version on PubMed Central for supplementary material.
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EGFR Epidermal growth factor receptor
AG-1478 anilinoquinazoline, a tyrosine kinase inhibitor specific for EGFR
PPP Picropodophyllin
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FIGURE 1. Microarray analysis of laser-capture microdissected (LCM) rat airway epithelia
(A) Light micrographs of the rat large airways before and after laser-capture microdissection
of epithelial cells. (B) Venn-diagram clustering of genes expression pattern obtained by
microarray analysis of LCM-captured epithelial cells from LPS-instilled and control rats.
(C) Heat-map displaying differential gene expression pattern (p<0.05) of microdissected
airway epithelia mRNA from rats instilled with LPS or non-instilled controls (n=3 rats per
group). (D) Relative quantities of Bcl-2, MUC5AC, IGF-1, and IL-1β mRNA levels in
LCM-captured epithelial cells from LPS-instilled rats compared to control rats as quantified
by qRT-PCR.
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FIGURE 2. IL-1β and IGF-1 induce Bcl-2 expression in airway epithelial cells
Bcl-2 mRNA levels in AALEB cells 24 h after treatment with rhIGF-1 (A) or rhIL-1β (B) as
quantified by qRT-PCR. (C) Bcl-2 protein levels in AALEBs following treatment with
IGF-1 (100 ng/ml) and IL-1β (5 ng/ml) compared to the non-treated cells and normalized to
the β-actin levels (n=3). The upper panel shows a representative immunoblot. (D) In-situ
analysis of Bcl-2 expression in AALEB cells by immunofluorescence following IGF-1 (100
ng/ml) and IL-1β (5 ng/ml) treatment. The Bcl-2-positive and total cells were counted 24 h
after treatment and data expressed as the percent of Bcl-2 positive cells (n=3), results shown
as mean ± SEM. * p<0.05, ** p<0.01, *** p<0.001. Scale bars, 10 µm.
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FIGURE 3. Intracellular IGF-1 mediates IL-1β- and IGF-1-induced Bcl-2 expression using both
EGFR and IGF-1R pathways
(A) Bcl-2 mRNA levels in AALEBs treated with IGF-1 and IL-1β in the presence or
absence of PPP (300 nM) or AG1478 (1 µM), tyrosine kinase inhibitors for IGF-1R and
EGFR, respectively (n=4). (B) Immunofluorescence analysis of intracellular-IGF-1-positive
(IC-IGF-1 pos) and Bcl-2-positive (Bcl-2 pos) AALEB cells following treatments with
IGF-1 or IL-1β in the presence or absence of PPP or AG1478 (n=4). Representative
micrographs showing AALEB cells expressing IC-IGF-1 (left panels, in red), Bcl-2 (middle
panels, in green), and merged image (right panels) denoting co-expression of IC-IGF-1 and
Bcl-2 following IGF-1(upper panels) and IL-1β (lower panels) treatments. (C) Changes in
the percentage of Bcl-2-positive cells in IGF-1 or IL-1β treated AALEB cells at 1, 2, 3, 4, 8
and 12 h (n=4). (D) Analysis of IGF-1 and Bcl-2 expression following IL-1β treatment in
AALEBs with blocked IGF-1 expression (n=4). The AALEB cells transfected with shIGF-1
(shRNA specific for IGF-1) and shCon (control shRNA) constructs were treated with IL-1β
(5 ng/ml) for 48 h before co-immunostaining for IGF-1 (red) and Bcl-2 (green). The percent
of IC-IGF-1- and Bcl-2-positive cells infected with shCon and shIGF-1 retroviral vectors
were quantified. (E) In-vivo analysis of Bcl-2 expression in rat airway epithelial cells
following intratracheal instillation of rat IGF-1. The micrographs show bronchial epithelium
of proximal airway (G-5) from vehicle-instilled (left panel) and IGF-1-instilled (right panel)
rat with arrow indicating Bcl-2-positive (red) cell. The numbers of Bcl-2 positive cells per
mm of basal lamina were counted (n=8 per group). Results shown as mean±SEM; * p<0.05;
** p<0.01; *** p<0.001; # p<0.05 compared to IGF-1-treated group; ψ p<0.05 compared to
IL-1β-treated group; scale = 10µ.
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FIGURE 4. IGF-1 induces Bcl-2 expression by increasing Bcl-2 mRNA stability in a mechanism
that involves the Bcl-2 P2 promoter region
(A) The calculated half-life of Bcl-2 mRNA in AALEB cells in the presence and absence of
rhIGF-1 (n=3) as described in Material and Methods. (B) Bcl-2 mRNA levels in AALEB
cells treated with nothing as control or with IGF-1 and transfected with nothing, empty
vector, or a vector carrying the P2 construct (681 bp). Transfected and non-transfected (NT)
cells were treated with IGF-1 for 4 h and Bcl-2 mRNA levels were analyzed by qRT-PCR
and were compared to the media-treated NT cells (denoted by empty bar) (n=4). (C) Bcl-2
mRNA levels following IGF-1 treatment of AALEB cells transfected with various deletion-
constructs of P2-promoter region and a mutant P2 construct (mutP2). Left panel illustrates
the full-length P2 construct, various deletion-constructs, and the mutant P2 construct
(mutP2); the detailed description of constructs is in Material and Methods. All cells were
treated with rhIGF-1 for 4 h and Bcl-2 mRNA determined by qRT-PCR was normalized to
empty TA-cloning vector-transfected cells (n=4). Data shown as mean±SEM; * p<0.05, **
p<0.01.
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FIGURE 5. IC-IGF-1- and Bcl-2-positivity in airway epithelia of lungs with chronic
inflammation
(A) Bcl-2 mRNA levels in lung tissues of mice instilled with LPS or saline as quantified by
qRT-PCR. (B) Analysis of IC-IGF-1- and Bcl-2-positive airway epithelial cells in lung
tissues of mice instilled with LPS or saline. Mouse lung tissues harvested 3 d post LPS or
saline instillation. (C) IC-IGF-1- and Bcl-2-positive epithelial cells in airways of subjects
with cystic fibrosis (CF) or no lung disease. (D) Bcl-2 mRNA levels in lung tissues of mice
exposed to cigarette smoke (CS) or filtered air (FA) controls for 22 wks. (E) IC-IGF-1 and
Bcl-2-positive airway epithelial cells in lung tissues of mice exposed to CS or FA. (F)
IGF-1- and Bcl-2-positive airway epithelial cells in lung tissue from former-smokers with
chronic bronchitis (CB) compared to former-smokers with no CB. Lung tissue sections from
former-smokers with no CB (left panels) and with CB (right panels) were co-immunostained
for IGF-1 (top-panels) and Bcl-2 (middle panels). The bottom panels illustrate the merged
image showing the co-expression of IGF-1 and Bcl-2 in airway epithelial cells of CB (n=4
subjects/group). For B, C, E and F, lung tissue sections were immunostained for IC-IGF-1
(top-panels) and Bcl-2 (bottom panels) and number of positive-cells per mm basal lamina
were quantified (n=4 /group). Results shown as mean±SEM. * p<0.05; *** p<0.0001; scale
= 10µ.
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FIGURE 6. A schematic representation of a proposed molecular pathway by which IL-1β and
IGF-1 induce IC-IGF-1 and Bcl-2-expression
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Table 1





Age* 35.3 ± 21.7 29.3 ± 9.5
Gender, M/F 3/0 4/0
Diagnosis N/A 3 DF/DF
1, DF/621+1G>T
*
Mean ± SD; CF = cystic fibrosis; M = male; F = female; DF= deletion of phenylalanine; G > T = transversion mutation
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Table 2





Age* 62.4 ± 4.3 59.5 ± 10.2
Gender, M/F 2/3 4/0
Smoking packs/y* 36.8 ± 11.9 51.8 ± 28.8
Stop Smoking (Y)* 13.0 ± 6.0 10.5 ± 10.0
*
Mean ± SD; CB = chronic bronchitis; M = male; F = female; PY = Pack per Year; Y = years
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